CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Clinical safety rating: safe
CNS depressants may enhance sedative effects Abrupt discontinuation can cause rebound hypertension and nervousness.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic outflow from the CNS, decreasing peripheral resistance and heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
| Metabolism | Clonidine: hepatic metabolism (CYP2D6). Chlorthalidone: hepatic metabolism (minimal); primarily excreted unchanged in urine. |
| Excretion | Clonidine: ~40-60% excreted unchanged in urine, remainder as metabolites; renal elimination accounts for ~50-65% of total clearance. Chlorthalidone: ~50-65% excreted unchanged in urine, with ~30-50% undergoing renal tubular secretion; minimal biliary/fecal elimination (<10%). |
| Half-life | Clonidine: 12.7-16.9 hours (terminal), prolonged in renal impairment (up to 40 hours). Chlorthalidone: 40-60 hours (terminal), allowing once-daily dosing. |
| Protein binding | Clonidine: 20-40% (primarily albumin). Chlorthalidone: ~75% (primarily albumin and erythrocytes). |
| Volume of Distribution | Clonidine: 2.9-4.9 L/kg, indicating extensive tissue distribution. Chlorthalidone: 3.0-5.0 L/kg, implying high tissue affinity (especially erythrocytes and vascular smooth muscle). |
| Bioavailability | Clonidine: Oral ~75-95% (first-pass metabolism minimal); transdermal ~60% of system dose (absorption rate-limited). Chlorthalidone: Oral ~65-70% (affected by food; absorption complete but saturable). |
| Onset of Action | Clonidine: Oral antihypertensive effect begins within 0.5-1 hour (peak plasma at 3-5 hours); transdermal: 2-3 days (slow onset). Chlorthalidone: Oral diuretic effect begins within 2-3 hours, peak at 4-6 hours. |
| Duration of Action | Clonidine: Oral 6-8 hours (antihypertensive); transdermal up to 7 days. Chlorthalidone: Diuretic effect lasts 24-72 hours, antihypertensive effect 24-48 hours. |
Oral: 1 tablet (0.1 mg clonidine/15 mg chlorthalidone) once daily, titrated up to maximum 4 tablets daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: Reduce dose to 1 tablet daily. GFR <30 mL/min: Avoid use. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Avoid use due to reduced clearance and risk of hypotension. |
| Pediatric use | Not recommended in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 0.1 mg clonidine/15 mg chlorthalidone once daily. Titrate slowly; monitor for hypotension, electrolyte imbalances, and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants may enhance sedative effects Abrupt discontinuation can cause rebound hypertension and nervousness.
| FDA category | Animal |
| Breastfeeding | Clonidine: Excreted in breast milk; M/P ratio ~1.5. Monitor infant for hypotension, drowsiness. Chlorthalidone: Excreted in breast milk; M/P ratio unknown; may suppress lactation; avoid in breastfeeding. |
| Teratogenic Risk | Clonidine: Limited human data; animal studies show increased fetal resorptions and growth retardation at high doses. Use only if benefit outweighs risk. Chlorthalidone: Avoid in pregnancy, especially 2nd and 3rd trimesters, as thiazide diuretics cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Not recommended for gestational hypertension. |
■ FDA Black Box Warning
None
| Common Effects | ADHD |
| Serious Effects |
["Hypersensitivity to clonidine or chlorthalidone","Anuria","Severe renal impairment (CrCl <30 mL/min)","Uncontrolled arrhythmias","Concurrent use with other antihypertensives (caution)"]
| Precautions | ["Rebound hypertension upon abrupt discontinuation","Bradycardia and heart block","Orthostatic hypotension","Electrolyte imbalances (hypokalemia, hyponatremia)","Renal impairment","Sedation and dizziness"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, electrolytes, renal function. Fetal monitoring with ultrasound for growth restriction, and nonstress test in third trimester. Neonatal monitoring for hypotension, bradycardia, and electrolyte imbalances. |
| Fertility Effects | Clonidine: No reported effect on fertility. Chlorthalidone: No direct evidence of impaired fertility, but thiazides may cause electrolyte disturbances that could theoretically affect fertility. |